[Uptake of DL-3-123I-iodo-alpha-methyltyrosine in recurrent brain tumors]. / Anreicherung von DL-3-123I-Jod-alpha-methyltyrosin in Hirntumorrezidiven.
Nuklearmedizin
; 34(2): 71-5, 1995 Apr.
Article
em De
| MEDLINE
| ID: mdl-7761277
ABSTRACT
DL-3-123I-iodo-alpha-methyltyrosine (123I-IMT) is a radiopharmacon which concentrates in brain tumors and can be employed in SPECT. We performed 20 studies in 16 patients after neurosurgery for malignant brain tumors (localization of the primary tumor by CT/MRI). Tumor/non-tumor ratios (T/NT) were calculated in ROI-technique. In 17 cases there was a recurrence or tumor remnant. 14/17 were detectable by increased uptake (T/NT 1.43-2.25). The scans were correlated with CT/MRI studies and validated by biopsy (6/14) or follow-up. All 3 patients without recurrence (neuroradiological follow-up over 6-24 months) had a negative scan. 123I-IMT scintigraphy provides complementary information to CT and MRI. In equivocal neuroradiological or clinical cases it may be valuable in the detection of tumor recurrences and allows an earlier onset of therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Radioisótopos do Iodo
/
Metiltirosinas
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
De
Revista:
Nuklearmedizin
Ano de publicação:
1995
Tipo de documento:
Article